SLC5A2 and type 2 diabetes mellitus: Further studies with an introduction of SGLT2 inhibitor at different timing and a longer follow up period are needed to evaluate whether SGLT2 inhibitors affect cardiac sympathetic nerve activity or not in patients with AMI and T2DM.